Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors. - Wikidata - awgldk - TriplyDB

Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors.

Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors.

http://www.wikidata.org/entity/Q37418248

about

Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs Cell Death Conversion under Hypoxic Condition in Tumor Development and Therapy Switching off malignant mesothelioma: exploiting the hypoxic microenvironment Bis-picolinamide Ruthenium(III) Dihalide Complexes: Dichloride-to-Diiodide Exchange Generates Single trans Isomers with High Potency and Cancer Cell Selectivity.Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism.Tirapazamine has no Effect on Hepatotoxicity of Cisplatin and 5-fluorouracil but Interacts with Doxorubicin Leading to Side Changes in Redox Equilibrium.Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer.

P2860

Q26774750-39FD7687-AF2B-43E4-AF9E-D6DCC9A89899 Q26778008-44F2F29A-35F8-475C-9519-1B16AEFDE26E Q29248727-3CD55806-544A-4CCA-B346-D52E6F4B2053 Q36287265-7C450E0D-E2C2-4B2E-9A9B-C6D0AD713A8A Q38705051-6A18BB32-A505-43CA-983D-115C8B5AC825 Q50944606-DC825591-4CD4-4785-B67B-7892AF8E9AC7 Q53144349-9AC512CE-1ECD-4093-A652-E620109A80ED Q55400356-98755404-E256-40F2-A033-D4755F50B966

P2860

Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors.

http://www.wikidata.org/entity/Q37418248

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Hypoxia modulates the activity ...... ed tyrosine kinase inhibitors.

@en

Hypoxia modulates the activity ...... ed tyrosine kinase inhibitors.

@nl

type

label

Hypoxia modulates the activity ...... ed tyrosine kinase inhibitors.

@en

Hypoxia modulates the activity ...... ed tyrosine kinase inhibitors.

@nl

prefLabel

Hypoxia modulates the activity ...... ed tyrosine kinase inhibitors.

@en

Hypoxia modulates the activity ...... ed tyrosine kinase inhibitors.

@nl

P1433

Q37418248-7B3C8F19-CBD1-4516-A469-6EA37FE21757

P1476

Q37418248-D38D8B63-9B5C-4CEC-BA27-E6060C59F9E4

P2093

Q37418248-1DCA43F5-9E5A-4D8C-858E-D23A45176033

Q37418248-3E827E28-9EB3-435D-B3DA-3E14E152C37C

Q37418248-8FA44688-2F13-4863-ACEE-13F07F2CEF28

Q37418248-99A946E6-84EA-4C45-9481-214A2B275567

Q37418248-A6E8DBF2-A826-4E74-A7AF-9C2C80F275A2

Q37418248-CD64A441-A237-49BA-8BB1-9C5D88414376

Q37418248-D1DADBFF-14E9-4F0B-8F5B-7D36D5732176

P2860

Q37418248-008A2775-76F0-4451-91E6-A16F379A4E2C

Q37418248-04D5F2AC-8780-4256-B9E9-061FAF0C7A1F

Q37418248-051F3E55-5EFF-40F9-BEA4-C59C3834DD2A

Q37418248-095E5E0F-2F86-4DDF-BA46-03862CCA3554

Q37418248-0C05ABD4-1CBB-44CA-ADEC-A46F9FBA2D42

Q37418248-0D77E4C1-4028-4196-92C5-CBEBFB4EDF28

Q37418248-12058FA7-1983-43FF-B77F-45C2E14E550A

Q37418248-15F8AB97-9C42-4B9B-8987-64DEA9C753E0

Q37418248-166313D7-F8BF-4E7C-93D8-AA041AFA894D

Q37418248-17850952-5ED0-4C0A-B7FA-F9FE198405E2

P304

Q37418248-5D32FBD1-1D72-4494-AD65-005A03C36925

P31

Q37418248-77F00C12-0E02-46F6-911C-5CFB1251ABC6

P356

Q37418248-0851F619-ED7E-4F48-A75B-87FBCC23C371

P407

Q37418248-F59064F9-D7D7-48A0-A3FD-70AA49254A29

P433

Q37418248-7945A757-96AE-4D64-9B28-2F31B1229EFA

P478

Q37418248-62FB2421-89DF-4052-B35B-030E329292F9

P50

Q37418248-7B7F4934-5947-420C-B549-49AC47ACF8CE

Q37418248-E3F27A33-AE84-467E-AC3F-9C1125BBCA3E

Q37418248-EB589E97-EBEB-4237-91A8-F2268C4AE94A

P577

Q37418248-AF46782B-FF43-4A3E-B8B2-CCB8B3146A8F

P5875

Q37418248-14CEEABE-73FD-4050-BF20-89E0CFFA8FD0

P698

Q37418248-3DE09413-BC5B-4447-97C1-F4164CD18C83

P921

Q37418248-01A32B09-8DD8-4A2C-A5CC-193BF1C871E2

P932

Q37418248-7F1EC341-0F7E-4DF9-942B-36AA70273B8C

P356

P1433

British Journal of Pharmacology

P1476

Hypoxia modulates the activity ...... ed tyrosine kinase inhibitors.

@en

P2093

K Rockley

http://www.w3.org/2001/XMLSchema#string

M Ahmadi

http://www.w3.org/2001/XMLSchema#string

M Sadiq

http://www.w3.org/2001/XMLSchema#string

R Lokwani

http://www.w3.org/2001/XMLSchema#string

S Begum

http://www.w3.org/2001/XMLSchema#string

S Chintamaneni

http://www.w3.org/2001/XMLSchema#string

Z Ahmadihosseini

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting Src family kinases in anti-cancer therapies: turning promise into triumph

Src kinase regulation by phosphorylation and dephosphorylation

Drug penetration in solid tumours

Targeting hypoxia in cancer therapy

High interstitial fluid pressure - an obstacle in cancer therapy

A renaissance for SRC

A side order of stem cells: the SP phenotype.

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients.

Oncogenic viral protein HPV E7 up-regulates the SIRT1 longevity protein in human cervical cancer cells

Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.

P304

224-236

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BPH.12438

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

171

http://www.w3.org/2001/XMLSchema#string

P50

Roger M. Phillips

Simon J Allison

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257749988

http://www.w3.org/2001/XMLSchema#string

P698

24117380

http://www.w3.org/2001/XMLSchema#string

P921

P932

3874709

http://www.w3.org/2001/XMLSchema#string